A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Actym Therapeutics, Inc.
Symphogen A/S
NGM Biopharmaceuticals, Inc
University of California, San Diego
NGM Biopharmaceuticals, Inc
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie